From the American Academy of Ophthalmology

This prospective, multicenter trial assessed the efficacy and safety of adalimumab, a fully human anti-TNF monoclonal antibody, in 31 patients with refractory uveitis. Treatment was found safe and effective in 68 percent at 10 weeks. However relapsing inflammation reduced the success rate at one year to 39 percent, perhaps due to the refractory nature of the population and strict criteria for treatment success. Treatment-limiting toxicity was not identified in any patient. The most common reason for study termination was primary or secondary inefficacy. British Journal of Ophthalmology, April 2013